Buscar
Mostrando ítems 1-1 de 1
Artículo
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
(Nature publishing group, 2018)
Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis ...